Anticoagulant use and hemorrhage risk modify the eligible population for anti-amyloid antibody treatment.

Evidence span

Anticoagulant use and hemorrhage risk modify the eligible population for anti-amyloid antibody treatment.

Method & conditions

Evidence type

observational

Method

manual state transition

Species

Homo sapiens

Conditions

Treatment selection for anti-amyloid monoclonal antibodies; ARIA-H and intracerebral hemorrhage risk context.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required